Inhibrx Biosciences, Inc. (INBX)
(Delayed Data from NSDQ)
$20.94 USD
-0.87 (-3.97%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $20.91 -0.03 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Inhibrx Biosciences, Inc.'s return on equity, or ROE, is -85.12% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.42%. While this shows that INBX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
INBX 20.94 -0.87(-3.97%)
Will INBX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for INBX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for INBX
Inhibrx Biosciences: Seeing Soon If The Momentum Is Just Hype
Noteworthy Tuesday Option Activity: INBX, ODP, AZO
Bullish Two Hundred Day Moving Average Cross - INBX
Inhibrx Biosciences Concludes 2025 Annual Stockholders Meeting
Analysts’ Opinions Are Mixed on These NA Stocks: Ibotta, Inc. Class A (IBTA) and Inhibrx Biosciences Inc (INBX)